Vishal Goyal

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh

Ridwanur Rahman, Vishal Goyal, Rashidul Haque et al. · PLoS neglected tropical diseases · 2017 · 73 citations · Full text

AmBisome Monotherapy and Combination AmBisome–Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial

Sakib Burza, Raman Mahajan, Shahwar Kazmi et al. · Clinical Infectious Diseases · 2022 · 49 citations · Full text

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

Isabelle Andrieux‐Meyer, Soek-Siam Tan, Sombat Thanprasertsuk et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 36 citations · Full text

Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India

Vishal Goyal, Vidya Nand Rabi Das, Shambhu Nath Singh et al. · PLoS neglected tropical diseases · 2020 · 30 citations · Full text

Klippel‐Trenaunay Syndrome with a Life‐Threatening Thromboembolic Event

Kamal Aggarwal, Vijay Kumar Jain, Sanjeev Gupta et al. · The Journal of Dermatology · 2003 · 24 citations